WELCOME 2021
The Virtual E-Cigarette Summit USA – May 2021
The 2020 USA E-Cigarette Summit was regrettably cancelled, due to the COVID pandemic, which sadly is still preventing us from coming together as a global community. Following the success of our London Virtual Summit, we have taken the decision to move our Washington Summit on-line for the 2021 edition.
We are not short of content for this year and are now starting the process of finalizing speaker availability. We will confirm our dates as soon as possible, but it is likely to be a 2 day event in the week commencing 17th May. We hope you will be able to join us.
The information below and on the rest of this website pertains to the 2019 Summit – copies of the powerpoint slides and videos of the 2019 Summit can be found here.
Since the inaugural US Summit in 2017 which welcomed over 300 attendees, the tobacco control and policy landscape has continued to change. This year’s E-Cigarette Summit USA comes at a major US policy and regulatory crossroads and looks to provide an evidence based environment that encourages open and respectful dialogue on the key science and current public health topics, with a single aim of reducing smoking related death and disease.
The role that e-cigarettes could play in ending or extending the smoking epidemic is likely to remain one of the most fiercely fought debates in public health history. We cannot answer every question yet, but we believe that progress is not only possible but imperative. These first important steps to regulate an entirely novel product category will set the agenda for decades to come and is likely to be viewed as a pivotal era in both tobacco control and combustible tobacco use in the future.
SUMMIT CHAIR 2020
Prof Thomas Glynn
Stanford University School of Medicine
Prof Thomas J. Glynn, Stanford University School of Medicine
CONFIRMED SUMMIT SPEAKERS 2020
Prof Dorothy Hatsukami
Professor, Department of Psychiatry
Associate Director of Cancer Prevention and Control for the Masonic Cancer Center, University of Minnesota
Prof Jasjit S. Ahluwalia
Professor, Behavioural and Social Sciences & Internal Medicine
Brown University, School of Public Health & Alpert School of Medicine
Dr. Nancy A. Rigotti, MD
Professor of Medicine, Harvard Medical School
Director, Tobacco Research & Treatment Center, Massachusetts General Hospital, Boston
Kathleen Crosby
Director, Office of Health Communication & Education
FDA Center for Tobacco Products
Prof Richard Miech
Principal Investigator, Monitoring the Future
Institute for Social Research, Universithy of Michigan
Dr Mike Cummings
Professor, Dep't Psychiatry & Behavioural Sciences
Medical University of South Carolina
Pamela Kaufman
Morgan Stanley
Prof Kenneth Warner
Professor Emeritus and Dean Emeritus
School of Public Health, University of Michigan
Dr Ray Niaura
Director for Science
Schroeder Institute at Truth Initiative
Prof Thomas J. Glynn, PhD
Adjunct Lecturer
Stanford Prevention Research Centre, Stanford University School of Medicine
Matthew R. Holman
Director, Office of Science (OS),Center for Tobacco Products (CTP)
U.S. Food and Drug Administration
Professor Ann McNeill
Professor of Tobacco Addiction
UK Centre for Tobacco and Alcohol Studies (UKCTAS), Kings College London
Prof Steven A. Schroeder MD
Distinguished Professor of Health and Healthcare
University of California, San Francisco & Director, Smoking Cessation Leadership Center
Prof Neal L. Benowitz
Professor of Medicine and Bioengineering & Theapeutic Sciences
University of California, San Franciso
Ass’t Prof Jennifer Pearson
Assistant Professor
University of Nevado, Reno
Prof Andrea Villanti
Associate Professor of Psychiatry and Psychology
Vermont Center on Behavior & Health, at the University of Vermont
WHAT QUESTIONS WILL BE EXPLORED?
The E-Cigarette Summit provides an evidence based environment that encourages open and respectful dialogue on the key science and current public health topics. The format includes high level briefings from global experts followed by panel discussions and audience Q&A.
- What are the key considerations for prudent regulation of e-cigarettes?
- How do we maximize benefits for smokers and minimize potential harms for youth?
- Understanding youth use – how should data be interpreted and presented?
- How do we educate youth without confusing adult smokers
- How should the evidence on e-cigarettes and the harm continuum be communicated to the American public – how can we better help the public understand relative risks?
- Is the current and proposed regulatory regime for e-cigarettes fit for purpose or does it need to be reformed and, if so, what needs to be considered to achieve maximum benefits for public health?
- Are American youth experimenting with e-cigarettes more than other countries – what are the appropriate measures?
- Is dual use an important step in cessation or a failing of harm reduction?
- What direction should the FDA take with e-cigarettes and tobacco control – what are the main priorities for current smokers? And for preventing youth initiation? Are these two priorities compatible?
- Current and future research priorities
- Why has tobacco harm reduction proved to be such a divisive issue – how can we improve dialogue and collaboration?
WHO SHOULD ATTEND
The E-Cigarette Summit is particularly relevant to:
- Regulators and policy advisors
- Health providers and public health advocates
- National, state and local legislators and their staffs
- Public health professionals
- Scientific/research community
- Medical and health professionals
- e-cigarette industry stakeholders
WHO SHOULD ATTEND
- Regulators and policy advisors
- Health providers and public health advocates
- National, state and local legislators and their staffs
- Public health professionals
- Scientific/research community
- Medical and health professionals
- e-cigarette industry stakeholders
